2. Academic Validation
  3. Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821

Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821

  • Bioorg Med Chem Lett. 2016 Jul 1;26(13):3122-3126. doi: 10.1016/j.bmcl.2016.04.090.
Laureen C Colis 1,  Seth B Herzon 2
Affiliations

Affiliations

  • 1 Department of Chemistry, Yale University, New Haven, CT 06520, United States.
  • 2 Department of Chemistry, Yale University, New Haven, CT 06520, United States; Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520, United States. Electronic address: seth.herzon@yale.edu.
PMID: 27177826 DOI: 10.1016/j.bmcl.2016.04.090
Abstract

(-)-Lomaiviticin A (1) is a cytotoxic Bacterial metabolite that induces double-strand breaks in DNA. Here we show that the cytotoxicity of (-)-lomaiviticin A (1) is synergistically potentiated in the presence of VE-821 (7), an inhibitor of ataxia telangiectasia and Rad3-related protein (ATR). While 0.5nM 1 or 10μM 7 alone are non-lethal to K562 cells, co-incubation of the two leads to high levels of cell kill (81% and 94% after 24 and 48h, respectively). Mechanistic data indicate that cells treated with 1 and 7 suffer extensive DNA double-strand breaks and Apoptosis. These data suggest combinations of 1 and 7 may be a valuable chemotherapeutic strategy.

Keywords

Cancer; Chemotherapy; DNA; Lomaiviticin; Natural product; Synergism.

Figures